KK
TRDA icon

KLP Kapitalforvaltning’s Entrada Therapeutics TRDA Stock Holding History

KLP Kapitalforvaltning’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,100
Closed -$19K – 2260
2025
Q1 		$19K Hold
2,100
– – ﹤0.01% 2246
2024
Q4 		$36.3K Buy
+2,100
New +$38K ﹤0.01% 2270

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

KLP Kapitalforvaltning's TRDA Position: Q2 2025 in Review

KLP Kapitalforvaltning sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 2,100 shares — an estimated $19K sold.

KLP Kapitalforvaltning first reported a position in TRDA in Q4 2024 and held it in 2 quarters. The position peaked at $36.3K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • KLP Kapitalforvaltning reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • KLP Kapitalforvaltning sold 2,100 Entrada Therapeutics shares in Q2 2025, an estimated $19K.
  • KLP Kapitalforvaltning first reported a position in Entrada Therapeutics in Q4 2024 and held it in 2 quarters.
  • KLP Kapitalforvaltning's Entrada Therapeutics position peaked at $36.3K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2025, filed 23 Jul 2025.